Gilead Sciences (GILD) Target Lifted at Needham & Company Post Q4

February 5, 2014 6:52 AM EST Send to a Friend
Get Alerts GILD Hot Sheet
Price: $100.55 -0.55%

Rating Summary:
    23 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 7 | Down: 12 | New: 23
Trade GILD Now!
Join SI Premium – FREE
Needham & Company analyst Alan Carr reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised his price target from $85 to $95 following Q4 results.

"Gilead reported $3.04B in 4Q13 product sales, above our $2.76B estimate. Strong sales were driven in part by $130-150M in inventory stocking. Non-GAAP EPS of $0.55 was above our $0.47 and consensus $0.50 estimates. No Sovaldi sales guidance was provided. Sovaldi use by GT (70% GT1; 17% GT2; 12% GT3) appears to follow the broad U.S. HCV population, prompting mgmt to comment that patients may not be waiting for approval of an all-oral regimen in 4Q14. We have adjusted our Sovaldi estimates accordingly."

1Q14 and 2014 total revenue estimates are $4.04B (new) and $16.5B (was $13.9B). 1Q14 and 2014 WW single agent Sovaldi sales estimates are $1.13B (new) and $4.34B (was $1.78B).

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $82.02 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Needham & Company

Add Your Comment